Eptastigmine

A detailed overview of the drug Eptastigmine

CaptionSynonyms

Eptastigmine

Drug Information
Image	200
Identifiers DrugBank ChEBI		Chemical Data Molecular Weight

Eptastigmine is a cholinesterase inhibitor that was investigated for the treatment of Alzheimer's disease. It is a derivative of physostigmine, a naturally occurring alkaloid, and was developed to improve upon the pharmacokinetic and side effect profile of its predecessor.

Pharmacology

Eptastigmine functions by inhibiting the enzyme acetylcholinesterase, which is responsible for the breakdown of acetylcholine in the synaptic cleft. By preventing the degradation of acetylcholine, eptastigmine increases the concentration of this neurotransmitter in the brain, thereby enhancing cholinergic transmission. This mechanism is particularly beneficial in conditions like Alzheimer's disease, where there is a notable deficit in cholinergic activity.

Clinical Trials

Eptastigmine underwent several clinical trials to assess its efficacy and safety in patients with Alzheimer's disease. Initial studies showed promise, with improvements in cognitive function and daily living activities. However, subsequent trials revealed significant adverse effects, including gastrointestinal disturbances and hepatotoxicity, which led to the discontinuation of its development.

Adverse Effects

The most common side effects associated with eptastigmine include nausea, vomiting, diarrhea, and abdominal pain. These are typical of cholinesterase inhibitors due to increased cholinergic activity in the gastrointestinal tract. More serious adverse effects, such as liver toxicity, were observed in later trials, which ultimately halted further research into the drug.

Chemical Properties

Eptastigmine is a synthetic compound with the chemical formula C₁₇H₂₆N₂O₃. It is structurally related to physostigmine but has been modified to enhance its pharmacokinetic properties. The compound is characterized by its ability to cross the blood-brain barrier, which is essential for its action in the central nervous system.

History and Development

Eptastigmine was developed in the 1990s as part of an effort to find more effective treatments for Alzheimer's disease. Despite promising early results, the drug's development was ultimately abandoned due to safety concerns. The lessons learned from eptastigmine's development have informed the design of newer cholinesterase inhibitors with improved safety profiles.

Also see

• Alzheimer's disease
• Cholinesterase inhibitor
• Physostigmine
• Acetylcholine
• Blood-brain barrier